Literature DB >> 22818188

Recombinant origin, contamination, and de-discovery of XMRV.

Krista Delviks-Frankenberry1, Oya Cingöz, John M Coffin, Vinay K Pathak.   

Abstract

The discovery and de-discovery of the xenotropic murine leukemia virus-related virus (XMRV) has been a tumultuous roller-coaster ride for scientists and patients. The initial associations of XMRV with chronic fatigue syndrome and prostate cancer, while providing much hope and optimism, have now been discredited and/or retracted following overwhelming evidence that (1) numerous patient cohorts from around the world are XMRV-negative, (2) the initial reports of XMRV-positive patients were due to contamination with mouse DNA, XMRV plasmid DNA, or virus from the 22Rv1 cell line and (3) XMRV is a laboratory-derived virus generated in the mid 1990s through recombination during passage of a prostate tumor xenograft in immuno-compromised mice. While these developments are disappointing to scientists and patients, they provide a valuable road map of potential pitfalls to the would-be microbe hunters. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2012        PMID: 22818188      PMCID: PMC3426297          DOI: 10.1016/j.coviro.2012.06.009

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  94 in total

1.  Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study.

Authors:  Graham Simmons; Simone A Glynn; Anthony L Komaroff; Judy A Mikovits; Leslie H Tobler; John Hackett; Ning Tang; William M Switzer; Walid Heneine; Indira K Hewlett; Jiangqin Zhao; Shyh-Ching Lo; Harvey J Alter; Jeffrey M Linnen; Kui Gao; John M Coffin; Mary F Kearney; Francis W Ruscetti; Max A Pfost; James Bethel; Steven Kleinman; Jerry A Holmberg; Michael P Busch
Journal:  Science       Date:  2011-09-22       Impact factor: 47.728

2.  XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH.

Authors:  Rebecca S Arnold; Natalia V Makarova; Adeboye O Osunkoya; Suganthi Suppiah; Takara A Scott; Nicole A Johnson; Sushma M Bhosle; Dennis Liotta; Eric Hunter; Fray F Marshall; Hinh Ly; Ross J Molinaro; Jerry L Blackwell; John A Petros
Journal:  Urology       Date:  2010-04       Impact factor: 2.649

3.  Recombinant origin of the retrovirus XMRV.

Authors:  Tobias Paprotka; Krista A Delviks-Frankenberry; Oya Cingöz; Anthony Martinez; Hsing-Jien Kung; Clifford G Tepper; Wei-Shau Hu; Matthew J Fivash; John M Coffin; Vinay K Pathak
Journal:  Science       Date:  2011-05-31       Impact factor: 47.728

4.  Absence of xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome.

Authors:  Harriet C T Groom; Virginie C Boucherit; Kerry Makinson; Edward Randal; Sarah Baptista; Suzanne Hagan; John W Gow; Frank M Mattes; Judith Breuer; Jonathan R Kerr; Jonathan P Stoye; Kate N Bishop
Journal:  Retrovirology       Date:  2010-02-15       Impact factor: 4.602

5.  Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States.

Authors:  William M Switzer; Hongwei Jia; Oliver Hohn; HaoQiang Zheng; Shaohua Tang; Anupama Shankar; Norbert Bannert; Graham Simmons; R Michael Hendry; Virginia R Falkenberg; William C Reeves; Walid Heneine
Journal:  Retrovirology       Date:  2010-07-01       Impact factor: 4.602

6.  Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections.

Authors:  Eleanor Barnes; Peter Flanagan; Anthony Brown; Nicola Robinson; Helen Brown; Myra McClure; Annette Oxenius; Jane Collier; Jonathan Weber; Huldrych F Günthard; Bernard Hirschel; Sarah Fidler; Rodney Phillips; John Frater
Journal:  J Infect Dis       Date:  2010-10-11       Impact factor: 5.226

7.  Characterization, mapping, and distribution of the two XMRV parental proviruses.

Authors:  Oya Cingöz; Tobias Paprotka; Krista A Delviks-Frankenberry; Sheryl Wildt; Wei-Shau Hu; Vinay K Pathak; John M Coffin
Journal:  J Virol       Date:  2011-10-26       Impact factor: 6.549

8.  Failure to detect Xenotropic murine leukaemia virus-related virus in Chinese patients with chronic fatigue syndrome.

Authors:  Ping Hong; Jinming Li; Yongzhe Li
Journal:  Virol J       Date:  2010-09-13       Impact factor: 4.099

9.  Analysis of XMRV integration sites from human prostate cancer tissues suggests PCR contamination rather than genuine human infection.

Authors:  Jeremy A Garson; Paul Kellam; Greg J Towers
Journal:  Retrovirology       Date:  2011-02-25       Impact factor: 4.602

10.  No evidence of XMRV or related retroviruses in a London HIV-1-positive patient cohort.

Authors:  Eleanor R Gray; Jeremy A Garson; Judith Breuer; Simon Edwards; Paul Kellam; Deenan Pillay; Greg J Towers
Journal:  PLoS One       Date:  2011-03-23       Impact factor: 3.240

View more
  21 in total

1.  KRAS-retroviral fusion transcripts and gene amplification in arsenic-transformed, human prostate CAsE-PE cancer cells.

Authors:  B Alex Merrick; Dhiral P Phadke; Meredith A Bostrom; Ruchir R Shah; Garron M Wright; Xinguo Wang; Oksana Gordon; Katherine E Pelch; Scott S Auerbach; Richard S Paules; Michael J DeVito; Michael P Waalkes; Erik J Tokar
Journal:  Toxicol Appl Pharmacol       Date:  2020-04-25       Impact factor: 4.219

2.  Ductal variant of prostate adenocarcinoma harbor Xenotropic murine leukemia virus related virus (XMRV) infection: a novel finding in subtype of prostate cancer.

Authors:  Faraz Ahmed Baig; Talat Mirza; Amna Hamid; Serajuddaula Syed; Qamar Jamal
Journal:  Turk J Urol       Date:  2017-07-31

3.  Lessons Learned from Mouse Mammary Tumor Virus in Animal Models.

Authors:  Jaquelin P Dudley; Tatyana V Golovkina; Susan R Ross
Journal:  ILAR J       Date:  2016

4.  Frequent proviral integration of the human betaretrovirus in biliary epithelium of patients with autoimmune and idiopathic liver disease.

Authors:  W Wang; S Indik; S T Wasilenko; A Faschinger; E J Carpenter; Z Tian; Y Zhang; G K-S Wong; A L Mason
Journal:  Aliment Pharmacol Ther       Date:  2014-12-18       Impact factor: 8.171

5.  Restoration of Endogenous Retrovirus Infectivity Impacts Mouse Cancer Models.

Authors:  Eleonora Ottina; Prisca Levy; Urszula Eksmond; Julia Merkenschlager; George R Young; Juliette Roels; Jonathan P Stoye; Thomas Tüting; Dinis P Calado; George Kassiotis
Journal:  Cancer Immunol Res       Date:  2018-08-24       Impact factor: 11.151

6.  Structural analysis of monomeric retroviral reverse transcriptase in complex with an RNA/DNA hybrid.

Authors:  Elzbieta Nowak; Wojciech Potrzebowski; Petr V Konarev; Jason W Rausch; Marion K Bona; Dmitri I Svergun; Janusz M Bujnicki; Stuart F J Le Grice; Marcin Nowotny
Journal:  Nucleic Acids Res       Date:  2013-02-04       Impact factor: 16.971

7.  Generation of multiple replication-competent retroviruses through recombination between PreXMRV-1 and PreXMRV-2.

Authors:  Krista Delviks-Frankenberry; Tobias Paprotka; Oya Cingöz; Sheryl Wildt; Wei-Shau Hu; John M Coffin; Vinay K Pathak
Journal:  J Virol       Date:  2013-08-21       Impact factor: 6.549

8.  Frequent infection of human cancer xenografts with murine endogenous retroviruses in vivo.

Authors:  Asif Naseer; Anne Terry; Kathryn Gilroy; Anna Kilbey; Ciorsdaidh Watts; Nancy Mackay; Margaret Bell; Susan Mason; Karen Blyth; Ewan Cameron; James C Neil
Journal:  Viruses       Date:  2015-04-17       Impact factor: 5.048

9.  Conference highlights of the 16th International Conference on Human Retrovirology: HTLV and related retroviruses, 26-30 June 2013, Montreal, Canada.

Authors:  Benoit Barbeau; John Hiscott; Ali Bazarbachi; Edgar Carvalho; Kathryn Jones; Fabiola Martin; Masao Matsuoka; Edward L Murphy; Lee Ratner; William M Switzer; Toshiki Watanabe
Journal:  Retrovirology       Date:  2014-02-24       Impact factor: 4.602

Review 10.  Endogenous retroviruses and the development of cancer.

Authors:  George Kassiotis
Journal:  J Immunol       Date:  2014-02-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.